Effects of Standardized Aerobic Exercise-Training on Neurocognitive and Neurodegeneration
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Alzheimer's Disease
- Sponsor
- Howard University
- Enrollment
- 73
- Locations
- 2
- Primary Endpoint
- AD Assessment Scale-Cognitive (ADAS-COG)
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The primary purpose of this pilot study is to determine whether African Americans with mild Alzheimer's disease (AD) can be enrolled and retained in a 6-month aerobic exercise-training study.
Detailed Description
This study will examine the effects of aerobic exercise-training on neurocognitive function, and on cerebral glucose homeostasis. It is yet to be determined whether African Americans with mild AD can be recruited into such a study, nor has the relationship of fitness adaptation to neurocognitive function been systematically examined in this population. In addition to the goal of assessing the intervention effects, the study will evaluate the differential relationships of APOE to aerobic fitness-induced changes in neurocognition. The long-term goal is to explore the mechanism by which fitness adaptation exerts an effect on neurocognition, notably, low levels of high-density lipoprotein cholesterol (HDL-C), elevated inflammation (C-reactive protein (CRP) and interleukins (IL-1A)), deranged glucose homeostasis, hypertension and endothelia dysfunction are precursors of arteriolosclerosis, decreased cerebral perfusion and oxygen deprivation, all of which may increase AD risk. Because many of these putative AD risk factors are susceptible to lifestyle alterations, the study will also assess their roles in aerobic fitness-related improvements in cognitive function and reduction in AD risk.
Investigators
Thomas Obisesan
Professor of Medicine
Howard University
Eligibility Criteria
Inclusion Criteria
- •Age over 60 years
- •Ability to exercise vigorously without harm
- •Study partner
- •In good general health
- •Willing to exercise for 6 months
- •Body Mass Index (BMI) less than 37
- •Women participants must be postmenopausal for at least 2 years, and maintain current hormone replacement therapy status and allowed medication usage for the duration of the study
Exclusion Criteria
- •MMSE score below 20
- •TG (Triglyceride) greater than 400 mg/dl
- •LDL-C levels greater than 95% or HDL-C levels less than 10% of age and sex-adjusted norms
Outcomes
Primary Outcomes
AD Assessment Scale-Cognitive (ADAS-COG)
Time Frame: baseline, 3 and 6 months
Secondary Outcomes
- Geriatric Depression Scale(baseline and 6 months)
- Logical Memory Test (Delayed Paragraph Recall)(baseline and 6 months)
- Neuropsychiatric Inventory Q (NPIQ)(baseline and 6 months)
- Activities of Daily Living (ADCS-ADL)(baseline and 6 months)
- PET imaging to measure cerebral glucose homeostasis/metabolism(baseline and 6 months)
- Mini-Mental State Exam (MMSE)(baseline, 3 and 6 months)
- CDR (Clinical Dementia Rating) Scale(baseline, 3 and 6 months)
- Visuospatial and Visuographic: Clock Drawing Test(baseline and 6 months)
- American National Adult Reading Test (ANART)(baseline and 6 months)